GlassScriptPhysician profile
Corrine Giggee
NPI 1467486480
$12,431.39
in general payments reported to CMS, 2019-2025
28 companies · $5,725 in 2025
The $5,725 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $1,292 · 2023: $2,063 · 2024: $2,792 · 2025: $5,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,935 · Consulting Fee: $4,495 · Travel and Lodging: $932 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,935.08 |
| Consulting Fee | $4,495.00 |
| Travel and Lodging | $931.74 |
| Education | $218.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $5,661.63 | 2024-2025 | Tremfya |
| Amgen INC. | $2,258.63 | 2021-2025 | Otezla, Enbrel, Tavneos |
| Janssen Biotech, INC. | $882.75 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $808.68 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $765.71 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $542.66 | 2021-2024 | Taltz, Olumiant |
| Ucb, INC. | $233.84 | 2021-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $201.67 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $190.03 | 2022-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.40 | 2023-2024 | Cyltezo |
| Astrazeneca Pharmaceuticals LP | $134.87 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $104.05 | 2021-2025 | |
| Pfizer INC. | $93.91 | 2021-2024 | |
| Glaxosmithkline, LLC. | $74.97 | 2022-2024 | Benlysta |
| Sun Pharmaceutical Industries INC. | $48.90 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $39.05 | 2025 | Korlym |
| Sobi, INC | $31.14 | 2022 | |
| Genentech USA, INC. | $30.36 | 2024 | Actemra |
| Radius Health, INC. | $30.28 | 2025 | Tymlos |
| Kiniksa Pharmaceuticals, LTD. | $27.81 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $21.66 | 2024 | Strensiq |
| Medtronic, INC. | $18.57 | 2024 | Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $16.75 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.43 | 2023 | Xifaxan |
| Sandoz INC. | $14.83 | 2024 | Hyrimoz |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 | |
| Fresenius Kabi USA, LLC | $14.19 | 2023 | Idacio |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrine Giggee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.